Literature DB >> 23296003

Dual role of immunomodulation by anticancer chemotherapy.

Michael R Shurin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296003      PMCID： PMC4045109          DOI： 10.1038/nm.3045

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  13 in total

1.  A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.

Authors:  N A Thornberry; H G Bull; J R Calaycay; K T Chapman; A D Howard; M J Kostura; D K Miller; S M Molineaux; J R Weidner; J Aunins
Journal:  Nature       Date:  1992-04-30       Impact factor: 49.962

Review 2.  Protumor vs antitumor functions of IL-17.

Authors:  Gopal Murugaiyan; Bhaskar Saha
Journal:  J Immunol       Date:  2009-10-01       Impact factor: 5.422

3.  Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.

Authors:  S Lacour; A Hammann; A Wotawa; L Corcos; E Solary; M T Dimanche-Boitrel
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

4.  IL-17 promotes tumor development through the induction of tumor promoting microenvironments at tumor sites and myeloid-derived suppressor cells.

Authors:  Donggou He; Hui Li; Nabiha Yusuf; Craig A Elmets; Jun Li; John D Mountz; Hui Xu
Journal:  J Immunol       Date:  2010-01-29       Impact factor: 5.422

5.  Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

Authors:  Eiji Suzuki; Veena Kapoor; Arminder Singh Jassar; Larry R Kaiser; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

Review 6.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.

Authors:  Leisha A Emens; Elizabeth M Jaffee
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

7.  Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

Authors:  M E Christine Lutsiak; Roshanak T Semnani; Roberto De Pascalis; Syed V S Kashmiri; Jeffrey Schlom; Helen Sabzevari
Journal:  Blood       Date:  2004-12-09       Impact factor: 22.113

8.  Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.

Authors:  Fumiaki Tanaka; Hiroshi Yamaguchi; Mitsuhiko Ohta; Kohjiro Mashino; Hideto Sonoda; Noriaki Sadanaga; Hiroshi Inoue; Masaki Mori
Journal:  Int J Cancer       Date:  2002-09-20       Impact factor: 7.396

9.  Endogenous IL-17 contributes to reduced tumor growth and metastasis.

Authors:  Ilona Kryczek; Shuang Wei; Wojciech Szeliga; Linhua Vatan; Weiping Zou
Journal:  Blood       Date:  2009-03-16       Impact factor: 22.113

10.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.

Authors:  Mélanie Bruchard; Grégoire Mignot; Valentin Derangère; Fanny Chalmin; Angélique Chevriaux; Frédérique Végran; Wilfrid Boireau; Benoit Simon; Bernhard Ryffel; Jean Louis Connat; Jean Kanellopoulos; François Martin; Cédric Rébé; Lionel Apetoh; François Ghiringhelli
Journal:  Nat Med       Date:  2012-12-02       Impact factor: 53.440
View more
  16 in total

1.  Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials.

Authors:  David A Reardon; Hideho Okada
Journal:  J Neurooncol       Date:  2015-02-24       Impact factor: 4.130

Review 2.  Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.

Authors:  David A Reardon; Mark R Gilbert; Wolfgang Wick; Linda Liau
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis.

Authors:  Ninu Maskey; Kai Li; Min Hu; Zhigao Xu; Chunwei Peng; Fang Yu; Hong Cao; Jiamei Chen; Yan Li; Guifang Yang
Journal:  Tumour Biol       Date:  2014-09-27

4.  Potentiating cancer vaccine efficacy in liver cancer.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Angela Mauriello; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

5.  Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy.

Authors:  Joshua P Landreneau; Michael R Shurin; Marianna V Agassandian; Anton A Keskinov; Yang Ma; Galina V Shurin
Journal:  Cancer Microenviron       Date:  2013-11-29

Review 6.  Chemotherapy remains an essential element of personalized care for persons with lung cancers.

Authors:  M D Hellmann; B T Li; J E Chaft; M G Kris
Journal:  Ann Oncol       Date:  2016-07-25       Impact factor: 32.976

7.  Clinical evaluation of systemic and local immune responses in cancer: time for integration.

Authors:  Dmitriy W Gutkin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2013-10-08       Impact factor: 6.968

Review 8.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

Review 9.  Tumor promoters: from chemicals to inflammatory proteins.

Authors:  Hirota Fujiki; Eisaburo Sueoka; Masami Suganuma
Journal:  J Cancer Res Clin Oncol       Date:  2013-06-12       Impact factor: 4.553

10.  IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer.

Authors:  Te-Chia Wu; Kangling Xu; Jan Martinek; Robyn R Young; Romain Banchereau; Joshy George; Jacob Turner; Kyung In Kim; Sandra Zurawski; Xuan Wang; Derek Blankenship; Hannah M Brookes; Florentina Marches; Gerlinde Obermoser; Elizabeth Lavecchio; Maren K Levin; Sookyoung Bae; Cheng-Han Chung; Jennifer L Smith; Alma-Martina Cepika; Kyp L Oxley; George J Snipes; Jacques Banchereau; Virginia Pascual; Joyce O'Shaughnessy; A Karolina Palucka
Journal:  Cancer Res       Date:  2018-07-16       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.